NEW YORK, December 31, 2025, 14:52 ET — Regular session
- Cytokinetics shares rose about 3.7% in afternoon trading, outperforming a softer broader market.
- A Form 4 filing showed the company’s chief commercial officer sold 1,809 shares this week.
- Investors are watching for Myqorzo pricing and early launch execution ahead of January availability.
Cytokinetics, Incorporated shares rose 3.7% to $63.63 in afternoon trading on Wednesday, after touching $64.40 earlier in the session. The stock traded as low as $60.87, while the S&P 500 tracker and Nasdaq 100 fund were both down about 0.4% to 0.5%.
The move matters because Cytokinetics is nearing its first U.S. commercial launch after winning FDA approval for Myqorzo (aficamten) this month. The company has said the drug should be available in the U.S. in the second half of January and will be distributed under a REMS program — a required safety program for drugs with serious risks — because it carries a boxed warning for heart failure.
That rollout pits Cytokinetics against Bristol Myers Squibb’s Camzyos, the only other approved cardiac myosin inhibitor for obstructive hypertrophic cardiomyopathy — a condition where the heart muscle thickens and can obstruct blood flow. “Myqorzo seems safer and easier to use compared to Camzyos,” Mizuho analyst Salim Syed said. Cytokinetics has said it will disclose the drug’s list price before the January launch and expects pricing in line with Camzyos. Reuters
A regulatory filing showed EVP and Chief Commercial Officer Andrew Callos sold 1,809 shares at $62.44 on Dec. 29, leaving him with 51,353 shares. The Form 4 indicated the transaction was made under a Rule 10b5-1 plan, a pre-arranged trading program that can allow insiders to sell shares on a set schedule.
Investors often read insider sales cautiously, but small, planned transactions are common in biotech as equity compensation vests. Traders were more focused on what the launch cadence implies for the company’s shift from clinical-stage to commercial.
Myqorzo works by inhibiting cardiac myosin, a protein involved in heart muscle contraction. The FDA approval requires ongoing echocardiogram monitoring, an operational detail investors see as important in how quickly cardiology practices adopt the drug.
Cytokinetics has traded between $29.31 and $70.98 over the past 52 weeks, leaving Wednesday’s level about 10% below the high. The stock has been choppy in late December, and average daily volume is roughly 1.17 million shares, according to historical data.
Biotech funds were steady on the day, offering little help or hindrance from the sector. That left Cytokinetics moving mostly on company-specific positioning and the near-term launch narrative.
What investors are watching next is straightforward: the list price, payer coverage and the pace of onboarding prescribers and pharmacies into the REMS system. Any early indication of prescription demand after launch could quickly reset revenue expectations for 2026.
